This study is not yet open for participant recruitment. Verified by University of Pittsburgh, August 2010 Official Title Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting Purpose The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine among males 18-24 years old, comparing an on-time administration […]
This study is currently recruiting participants. Verified by Mayo Clinic, July 2010 Official Title: Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Purpose The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of […]
This study is currently recruiting participants. Verified by Merck, February 2010 Official Title Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice Purpose This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the […]
This study is ongoing, but not recruiting participants. Official Title Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women – The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Detailed Description: The original base protocol was extended. Subjects in the placebo arm […]
VRBPAC Briefing Document Presented by Merck on 17 November 2010 Human papillomaviruses (HPV) cause a significant burden of benign and malignant anogenital disease in men and women. The HPV-related anogenital cancers all develop through a common pathogenetic process of neoplastic change that begins with the necessary event of HPV infection. After cervical cancer, the anogenital […]
INDICATIONS AND USAGE GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18 Genital warts (condyloma acuminata) caused by HPV types […]
France says the award winning advertising campaign for Gardasil is false and misleading. The Sanevax Team wants to know – Where was the press coverage when this happened? Why did no one break the news to the public?
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Jan 04, 2011 – Amidst all of the media hype surrounding HPV vaccines, the traditional press has remained silent on many critical issues, not the least of which occurred on the 31 of August 2010 in France. As of that date, Merck’s marketing partner for the HPV vaccine Gardasil, Sanofli-Pasteur, was officially prohibited from advertising Gardasil for cervical cancer prevention in France.
The FDA continues to spark controversy over Merck’s Gardasil vaccine, as they ignore scientific principles to grant approval for extended use as a preventative for anal cancer and anal intraepithelial neoplasm. The SaneVax Team wants to know why. PRLog December 30, 2010 FOR IMMEDIATE RELEASE PRLog (Press Release) – Dec 29, 2010 – Wednesday, December […]
Age of Autism “Today, Zeda still breathes through her trach and eats with a tube. She lives her life in a hospital bed in our living room, mostly non-responsive, with round the clock care and daily nursing visits.” (PR LOG) Nov 16, 2010 – Amy Castelbery Pingle, Indiana: When one thinks of vaccine injuries, they […]
PR Log 9 out of 10 parents want vaccine safety research conducted – the SaneVax Team agrees. FOR IMMEDIATE RELEASE PRLog (Press Release) – Nov 11, 2010 – The C.S. Mott Children’s National Poll on Children’s Health asked 1,621 U.S. parents to rate the importance of different types of medical research for children’s health.Survey results, […]
Age of Autism October 9, 2010 VAERS records currently contain 19,273 reports of adverse events and 81 deaths following HPV vaccination. New reports are coming in at a rate of 125+/week. Why are 39 states allowing juvenile detention center officials to grant consent for inmates? PRLog (Press Release) – Oct 07, 2010 – Under the […]
SEO Press Releases North Hollywood, CA, October 4, 2010 — North Hollywood, CA. S.A.N.E.Vax, Inc. http://sanevax.org has posted an evidence-based commentary by prominent pathologist, Sin Hang Lee, MD, advising women to continue their regular Papanicolaou (Pap) screenings, rather than solely relying on human papillomavirus (HPV) vaccination and colposcopic biopsies without a prior Pap smear cytology […]
To date, there have been 283 VAERS reports of abnormal Pap tests following HPV vaccination. Gardasil and Cervarix claim to offer protection against the most common HPV viruses associated with cervical cancer. What is wrong with this picture?
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Sep 20, 2010 – Both FDA approved HPV vaccines, Gardasil and Cervarix, claim to offer protection from infections by the human papillomavirus genotypes most commonly associated with precancerous lesions and cervical cancer, HPV-16 and HPV-18. The manufacturers are also beginning to claim there is evidence of cross-protection against HPV genotypes 31 and 45. There are at least 283 young women who probably do not believe these statements.
The Vaccine Adverse Event Reporting System (VAERS) is a voluntary system. There are no requirements or legal obligations to report new medical conditions (adverse events) which occur after vaccination. Current estimates say that only 1-10% of the people who actually experience adverse events file reports.
The SaneVax team is concerned that with only 1-10% reporting, there may be as many as 28,300 people who have experienced abnormal Pap tests after HPV vaccination. This is not acceptable collateral damage.